PDT Partners LLC Purchases 45,449 Shares of Qiagen (NYSE:QGEN)

PDT Partners LLC grew its holdings in Qiagen (NYSE:QGEN) by 77.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 104,424 shares of the company’s stock after purchasing an additional 45,449 shares during the quarter. PDT Partners LLC’s holdings in Qiagen were worth $4,759,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC increased its holdings in Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after purchasing an additional 500 shares during the last quarter. Toronto Dominion Bank acquired a new stake in shares of Qiagen in the 2nd quarter valued at approximately $27,000. Massmutual Trust Co. FSB ADV boosted its stake in Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after acquiring an additional 243 shares during the last quarter. CWM LLC grew its holdings in Qiagen by 12.0% during the second quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after purchasing an additional 269 shares during the period. Finally, Headlands Technologies LLC increased its stake in Qiagen by 396.6% in the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after purchasing an additional 2,189 shares in the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Trading Down 0.7 %

Shares of NYSE:QGEN opened at $43.43 on Friday. The stock has a market capitalization of $9.91 billion, a PE ratio of 111.36, a price-to-earnings-growth ratio of 3.39 and a beta of 0.41. The company’s 50-day moving average price is $43.25 and its two-hundred day moving average price is $43.73. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. Qiagen has a one year low of $39.03 and a one year high of $47.44.

Analyst Ratings Changes

QGEN has been the subject of several research analyst reports. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a report on Thursday, October 17th. Robert W. Baird boosted their target price on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, Hsbc Global Res upgraded Qiagen to a “hold” rating in a report on Thursday, October 17th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $50.88.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.